Spyre Therapeutics announced that its Compensation Committee approved stock options for 11,138 shares and 3,195 restricted stock units (RSUs) to two new non-executive employees as inducement awards. These awards, granted under the 2018 Equity Inducement Plan, are intended to attract and retain talent, with stock options priced at $95.51 and vesting over several years. This move supports Spyre's ongoing efforts to develop innovative therapies in immunology. The awards align with Nasdaq rules and reflect the company's commitment to building its workforce for future growth.
Spyre Therapeutics shares are trading higher, up 7.65% at USD 103.98 on Pluang. The stock is near its 52-week high of USD 108.92, reflecting strong market interest. These figures are as of Nov 07, 2026 04:21 WIB.
